Ikena Oncology, Inc. (IKNA) financial statements (2022 and earlier)

Company profile

Business Address 50 NORTHERN AVE.
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments232,217
Cash and cash equivalents232,217
Prepaid expense850
Other current assets629
Other undisclosed current assets2,820
Total current assets:236,516
Noncurrent Assets
Operating lease, right-of-use asset6,538
Property, plant and equipment2,439
Restricted cash and investments872
Other undisclosed noncurrent assets1,514
Total noncurrent assets:11,363
TOTAL ASSETS:247,879
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,723
Accounts payable2,384
Accrued liabilities530
Employee-related liabilities2,809
Deferred revenue17,100
Other liabilities26
Other undisclosed current liabilities4,340
Total current liabilities:27,189
Noncurrent Liabilities
Long-term debt and lease obligation5,135
Operating lease, liability5,135
Liabilities, other than long-term debt7,678
Deferred revenue7,678
Total noncurrent liabilities:12,813
Total liabilities:40,002
Stockholders' equity
Stockholders' equity attributable to parent207,877
Common stock36
Additional paid in capital353,295
Accumulated deficit(145,454)
Total stockholders' equity:207,877
TOTAL LIABILITIES AND EQUITY:247,879

Income statement (P&L) ($ in thousands)

12/31/2021
Revenues30,985
Gross profit:30,985
Operating expenses(65,123)
Operating loss:(34,138)
Nonoperating income
(Other Nonoperating income)
23
Net loss available to common stockholders, diluted:(34,115)

Comprehensive Income ($ in thousands)

12/31/2021
Net loss:(34,115)
Comprehensive loss, net of tax, attributable to parent:(34,115)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: